Genmab — December 2020
-
Er hexacd38 en del af den nuværende partneraftale med JnJ, med samme royalty og en
forlængelse af patentet? -
-
20% royalty til 2031, derefter 13-20%
-
Tak GB. Er det normalt der ikke fremgår end date på perioden med 13-20 %?
-
Med hexa-cd38 succes vil det fjerne en stor del af den potentielle downside på igangværende voldgift med JnJ?
-
Ja
-
Usmani havde forventet mere af dara/pom/dex https://twitter.com/szusmani/status/1335677535280128004?s=21
-
Usmani mener dara/kyp/dex er bedre egnet til revlimid refractionere patienter
-
-
Regeneron cd3/cd20 data https://twitter.com/thelancethaem/status/1335678158075473920?s=21
-
Mosunetusumab i DLBCL https://twitter.com/graham74gc/status/1335682600678068224?s=21
-
-
Induces complete pesonses with favorable safety profile:-)
-
Godt med CR’er umiddelbart - og imponerende ORR’er
-
SQ Epcoritamab...What an impressive BiAB ! Excellent response, SQ administration, very low grade CRS ! The race is on for
BiABs...THE future in B-NHL treatments -
-
Konsensus blandt onkologer er at det er rigtig godt
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind